Presynaptic dopamine receptors involved in the inhibition of noradrenaline and dopamine release in the human gastric and uterine arteries

Fundamental and Clinical Pharmacology

Volumn 13, Issue 6, 1999, Pages 662-670

  Morgadinho, Maria T ^a   Fontes Ribeiro, Carlos A ^a   Macedo, Tice R A ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Catecholamine release; D2 dopamine receptors; Human gastric artery; Human uterine artery; Presynaptic dopamine receptors

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NORADRENALIN; PRESYNAPTIC RECEPTOR; SULPIRIDE; YOHIMBINE;

ARTERY; ARTICLE; CATECHOLAMINE RELEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSTIMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SYMPATHETIC NERVE; UTERINE ARTERY;

EID: 0033403771     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1999.tb00378.x     Document Type: Article

References (21)

1. [1] Langer S.Z., Presynaptic regulation of the release of catacholamines, Pharmacol. Rev. 32 (1980) 337-362.
2. [2] Lokhandwala M.F., Barrett R.J., Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications, J. Auton. Pharmacol. 3 (1982) 189-215.
3. [3] Friedman D.J., Budai D., Krause D.N., Duckles S.P., Prejunctional inhibitory effect of a dopamine D-2 agonist, N-0437, on vascular adrenergic responses, J. Pharmacol. Exp. Ther. 250 (1989) 853-859.
4. [4] Soares-da-Silva P., Dopamine released from nerve terminals activates prejunctional dopamine receptors in dog mesenteric arterial vessels, Br. J. Pharmacol. 91 (1987) 591-599.
5. [5] Brodde O.E., Sub-classification of peripheral dopamine receptors, J. Auton. Pharmacol. (suppl.) 10 (1990) s5-s10.
6. [6] Bell C., Gillespie J.S., Macrae I.M., Release of noradrenaline and dopamine by nerve stimulation in the guinea-pig and rat vas deferens, Br. J. Pharmacol. 81 (1984) 563-569.
7. [7] Bradley T., Hjemdahl P., Further studies on renal nerve stimulation induced release of noradrenaline and dopamine from the canine kidney in situ, Acta Physiol. Scand. 122 (1984) 369-379.
8. [8] Soares-da-Silva P., A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery, Br. J. Pharmacol. 90 (1987) 91-98.
9. [9] Morgadinho M.T., Fontes Ribeiro C.A., Macedo T.R.A., Electrical stimulation-induced release of dopamine and noradrenaline in human blood vessels, Bioelectrochem. Bioenergetics 38 (1995) 281-287.
10. [10] Lokhandwala M.F., Steenberg M.L., Selective activation by LY-141865 and apomorphine of presynaptic dopamine receptors in the rat kidney and influence of stimulation parameters in the action of dopamine, J. Pharmacol. Exp. Ther. 228 (1984) 161-167.
11. [11] O'Conner S.E., Brown R.A., The pharmacology of sulpiride: A dopamine receptor antagonist, Gen. Pharmacol. 13 (1982) 185-193.
12. [12] Iorio L.C., Barnett A., Leitz F.H., Houser V.P., Korduba C.A., SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems, J. Pharmacol. Exp. Ter. 226 (1983) 462-468.
13. 3H]-SCH 23390 as a ligand, J. Auton. Pharmacol. 10 (1990) 373-383.
14. [14] Ohmori T., Koyama T., Yamashita I., Measurement of endogenous dopamine and norepinephrine release from super-fused slices of rat prefrontal cortex in vitro: modulation by D2 and α2 presynaptic receptors, Life Sci. 48 (1991) 283-289.
15. [15] Starke K., Presynaptic α-autoreceptors, Rev. Physiol. Biochem. Pharmacol. 107 (1987) 73-146.
16. [16] Dubocovich M.L., Langer S.Z., Dopamine and α adrenoceptor agonists inhibit neurotransmission in the cat spleen through different presynaptic receptors, J. Pharmacol. Exp. Ther. 212 (1980) 144-152.
17. [17] Willems J.L., Buylaert W.A., Lefebvre R.A., Bogaert M.G., Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system, Pharmacol. Rev. 37 (1985) 165-216.
18. [18] Soares-da-Silva P., Evidence for dopaminergic co-transmission in dog mesenteric arterial vessels, Br. J. Pharmacol. 95 (1988) 218-224.
19. [19] Soares-da-Silva P., The effects of quinpirole and fenoldopam on the potassium-evoked overflow of endogenous dopamine and noradrenaline in dog mesenteric arteries, Naunyn-Schmiedeberg's Arch. Pharmacol. 341 (1990) 37-42.
20. [20] Martin P.L., Kelly M., Cusack N.J., (-)-2-(N-Propyl-N-2-Thienylethylamino)-5-Hydroxytetralin (N-0923), a selective D2 dopamine receptor agonist demonstrates the presence of D2 dopamine receptors in the mouse vas deferens but not in the rat vas deferens, J. Pharmacol. Exp. Ther. 267 (1993) 1342-1348.
21. [21] Carratu M.R., Conte-Camerino D., De Serio A., Ferrari E., Mitolo-Chieppa D., Evidence for the existence of prejunctional receptor sites for dopamine in the mouse vas deferens, J. Auton. Nerv. Syst. 27 (1989) 221-228.